
- Burning Rock Biotech (BNR), a precision oncology company from China, has shown exceptional technical momentum and price appreciation.
- BNR has surged 405% over the past year, hitting a 2-year high on Wednesday.
- Despite strong technicals, BNR is a highly speculative and risky stock.
- Today’s Chart of the Day is not a buy recommendation. Investors should exercise caution, diversify, and use strict stop-loss strategies with BNR.